Ezquer, FernandoHuang, Ya-LinEzquer, Marcelo2022-11-142022-11-142022: Ezquer, F.; Huang, Y.-L.; Ezquer, M. New Perspectives to Improve Mesenchymal Stem Cell Therapies for Drug-Induced Liver Injury. Int. J. Mol. Sci. 2022, 23, 2669. https://doi.org/10.3390/ijms23052669https://doi.org/10.3390/ijms23052669http://hdl.handle.net/11447/6663Abstract: Drug-induced liver injury (DILI) is one of the leading causes of acute liver injury. Many factors may contribute to the susceptibility of patients to this condition, making DILI a global medical problem that has an impact on public health and the pharmaceutical industry. The use of mesenchymal stem cells (MSCs) has been at the forefront of regenerative medicine therapies for many years, including MSCs for the treatment of liver diseases. However, there is currently a huge gap between these experimental approaches and their application in clinical practice. In this concise review, we focus on the pathophysiology of DILI and highlight new experimental approaches conceived to improve cell-based therapy by the in vitro preconditioning of MSCs and/or the use of cell-free products as treatment for this liver condition. Finally, we discuss the advantages of new approaches, but also the current challenges that must be addressed in order to develop safer and more effective procedures that will allow cell-based therapies to reach clinical practice, enhancing the quality of life and prolonging the survival time of patients with DILI.enMesenchymal stem cellsDrug-induced liver injurySecretomeExosomesCell therapyArticle